Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement). Mineralys now owns lorundrostat-related patents and know-how previously licensed from Tanabe.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Mineralys now owns lorundrostat-related patents and know-how previously licensed from Tanabe
- License termination removes ongoing license framework but preserves Tanabe milestone payment obligations
- Up to $265.0 million remains payable upon first sale, sales targets, or second-indication commercialization
- $100.0 million could accelerate upon a change of control or exclusive U.S. partnering transaction
- Tanabe retains Japan negotiation rights until applicable milestone payments are achieved and paid
Item 1.02 · Termination of a Material Definitive Agreement
- License Agreement termination confirmed, with details incorporated from Item 1.01
- No material early termination penalties, limiting immediate cash impact
- Termination may alter Mineralys’s strategic or development plans tied to the licensed program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.